HOERSHOLM, Denmark, Feb. 1, 2006 (PRIMEZONE) -- Pharmexa has filed an application to obtain approval to initiate the phase III trial with GV1001 in Ireland. Further applications will be filed in a number of countries in the coming weeks. Pharmexa has now filed an application to the authorities in Ireland in order to obtain approval to initiate a phase III trial with GV1001 in inoperable patients with pancreatic cancer. Further applications are expected to be filed in the next two weeks in Sweden, Norway, the Netherlands, Australia and Spain. Thereafter the rest of the countries involved will follow.
